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ABSTRACT 
 
Introduction: AABB Standards requires that laboratories participate in a proficiency test (PT) 
program for critical analytes.  Institutions can purchase commercial PT materials; however, PT 
can also be performed through inter-laboratory exchange. We investigated the utility of 
allogeneic hematopoietic progenitor cell apheresis products (HPC-A) as an inter-laboratory PT 
challenge for total nucleated cell (TNC) and CD34 assessment. 
Methods: Three-year retrospective and comparative review of unrelated allogeneic HPC-A 
products received by the University of Michigan between 1/2011 and 12/2013.  Internal TNC 
and CD34 counts were compared to the external collecting facility by paired t-test and linear 
regression. The absolute and % difference between external and internal counts, and 95% limits 
of agreeability (95% LA) were determined. Results were analyzed relative to donor center 
location (international, domestic), time zone (domestic) and calendar year.   
Results: There was a strong correlation between internal and external TNC, regardless of donor 
center location or year.  For CD34, there was a good correlation between centers (R= 0.88-0.91; 
slope=0.95-0.98x) with a median difference of -1% (95% LA: -50%, +47%).  This was 
considerably better than commercial PT challenges, which showed a persistent negative bias for 
absolute CD34 and CD3 counts.  
Conclusion: Allogeneic HPC-A products represent an inter-laboratory PT exchange for all 
critical analytes, including TNC and CD34 counts, cell viability and sterility. Allogeneic HPC-A 
products, which are fresh and transported under validated conditions, are less subject to 
preanalytical variables that may impact commercial PT samples such as aliquoting and sample 
homogeneity, commercial additives, and sample stability during manufacturing and transport.  
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INTRODUCTION 
Both AABB and the Foundation for the Accreditation of Cell Therapy (FACT) require 
assessment and documentation of laboratory proficiency in cell therapy processes.
1,2
 FACT 
standard D8.1.4 requires a process for monitoring reliability, accuracy, precision and 
performance of laboratory test procedures, including documentation of ongoing proficiency 
testing.
2
 AABB Standards for Cell Therapy Services are more specific, mandating participation 
in a proficiency test (PT) program for each measured analyte (8.2).
1
 Moreover, US-based 
laboratories are required to participate in a CMS-approved PT program for each CLIA-regulated 
analyte. For other analytes, there must be a system for deeming the accuracy and reliability of 
test results (8.2.1).
1
 In cell therapy, critical analytes include the total nucleated cell count (TNC), 
CD34 count, CD34 viability and sterility testing, which are required for all cell therapy products 
per AABB standard 5.17A and FACT standards D8.1.3 and D8.7.
1,2
 In the United States, TNC, 
CD34 and cell viability are non-graded PT analytes, but are regulated and must be assessed twice 
yearly to determine the accuracy and reliability of the reported results. 
We have participated in the biannual College of American Pathology’s (CAP) stem cell 
processing (SCP) PT challenges for several years. Each CAP-SCP challenge includes two 
prepared samples resuspended in commercial tissue culture media supplemented with 10% 
human sera.
3-10 
Participants are asked to measure the TNC count, CD34 count, and cell viability 
per institutional procedures. The reported results are analyzed relative to instrumentation, 
reagents and CD34 testing platform (single- or dual-stage). Due to the small number of 
participants and wide variation in testing results, the CAP-SCP PT challenges are currently 
ungraded.  
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Another avenue for PT is inter-laboratory exchanges. This method is not uncommon for 
new molecular testing assays or infrequently performed assays.
11
 In this respect, allogeneic stem 
cell products procured through the NMDP can be considered an inter-laboratory PT challenge, 
since these products are tested by both collection and receiving facilities. Unlike commercial PT 
samples, allogeneic products are fresh and are not subject to dilution or modification by the 
addition of stabilizing agents or re-suspension in tissue culture media.
3-10,12-18
 To assess the 
utility of allogeneic products for PT, we compared the TNC and CD34 counts from 141 
peripheral blood hematopoietic progenitor cell apheresis units (HPC-A) received at our 
institution from external collection facilities over a 3-year period. 
 
METHODS 
Study Design:  
The study was a 3-year retrospective review of all unrelated allogeneic HPC-A units received by 
the University of Michigan between January 2011 and December 2013. External and internal 
testing results for the calculated absolute TNC and CD34 counts were compared and analyzed as 
an inter-laboratory PT challenge. Data from the external donor facility included the absolute 
TNC (x10
9
) and CD34 count (x10
6
) of each unit, product volume (mL), whether it was collected 
by a National Marrow Donor Program (NMDP) or non-NMDP donor facility, NMDP donor 
center identification number, donor center location (country, state), donor sex and age. Donor 
centers were classified as international, if located outside the United States, or domestic, if 
located within the continental United States. For domestic donor facilities, the time zone 
(Eastern, Central, Mountain, Pacific) was also included for analysis. Available internal 
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laboratory data included the absolute TNC and CD34 counts, cell viability, % MNC, hematocrit 
(%), platelet count (10
3
/µL) and transplant cell dose.  
 
Internal Cell Analysis  
Allogeneic products were tested for TNC count, CD34 count, cell viability and sterility testing 
upon receipt.  TNC, and complete blood count were performed using an automated cell counter 
(Sysmex XE-5000, Kobe, Japan). The WBC differential was determined by manual methods. Per 
protocol, samples with an initial WBC count over 300,000/µL were diluted 1:5 in commercial 
cell diluent (Cell Pack DCL, Sysmex) and re-analyzed.  
For CD34 analysis, a 0.5 mL aliquot was incubated with a cocktail containing antibodies 
against CD34, CD45, CD14 and 7-aminoactinomycin D (7-AAD) for 10 minutes, followed by 
red cell lysis and immediate analysis:  Samples were not subjected to a wash step or fixation 
prior to flow cytometry.  CD34 analysis was performed using a dual-stage, 4-color modified 
ISHAGE (International  Society for Hematotherapy and Graft Engineering) protocol on a Gallios 
multichannel flow cytometer (Beckman Coulter, Indianapolis, IN). Per ISHAGE, CD34 cells 
were identified through sequential gating using CD45, CD34, forward and side scatter (SS) to 
identify CD34+, CD45
dim
, SS
low
  HPC cells.
17,19
 In addition, samples were co-stained with an 
anti-CD14 to exclude CD34+, CD14+ cells.
14, 20-22
 Cell viability was determined with 7-AAD 
(Life Technologies, Carlsbad, CA).  A minimum of 100,000 total events and/or 2000 CD34 cell 
events were acquired per analysis. Anti-CD34 (clone 581, class III; phycoerythrin (PE) 
conjugate), anti-CD45 (clone J33, electron coupled dye (ECD) conjugate), anti-CD14 (clone 
RM052, fluorescein isothiocyanate (FITC) conjugate) were purchased from Beckman Coulter. 
Ammonium chloride lysing reagent was prepared fresh daily from stock reagents.  Daily quality 
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controls for flow cytometry included commercial reagents for CD34 and CD45 (Chex CD-Plus 
BC and CD-Chex CD34; Streck, Omaha, NE). 
 
Statistics:  
The TNC and CD34 counts for individual units as measured by the donor center (external) and 
our institution (internal) were compared by paired t-test (Fig. 1) and linear regression. In 
addition, the absolute difference between donor center and internal cell counts (external count – 
internal count) and the percent (%) difference (external count – internal count / external count) 
were also calculated. Results were reported as the mean ± standard deviation (x ± SD). The 95% 
limit of agreeability (95% LA) were calculated and plotted as described.
23,24
 Specifically, the % 
difference was plotted against the mean absolute CD34 count ([external count + internal count] ÷ 
2).  Results falling between the x ± 1.96SD were considered within the 95% LA. Differences 
between international and domestic HPC-A products were compared by standard t-test.  Linear 
regression, graphing and t-tests were performed using Kaleidograph (Synergy Software, 
Reading, PA). Catagorical variables were compared by chi square using EpiInfo (Centers for 
Disease Control, Atlanta, GA). 
 
CAP-SCP PT Analysis: 
CAP-SCP PT samples (2.5 mL sample) were shipped overnight with cold gel packs. Upon 
arrival, samples were mixed and sterilely split into four 0.5 mL aliquots in a biological hood for 
hematology, flow cytometry, gram stain and bacterial culture. With one exception, all samples 
were tested and analyzed on day of receipt per institutional protocols as described above. All 
samples were tested within 24 hours of receipt per CAP requirements.  
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TNC and WBC count were performed on Sysmex XE-5000. CD34 analysis was 
performed using a modified ISHAGE protocol as described above and reported as %CD34 and 
CD34 count (x10
6
).  In addition, the list mode data (LMD) files were re-analyzed at a later date 
by a second individual, who was blinded with regard to the original testing results. The %CD34 
was determined without 7-AAD gating as recommended by the United Kingdom National 
External Quality Assessment program (UK NEQA).
17
  
For analysis, our internal institutional CAP-SCP results for TNC and CD34 results were 
plotted against the manufacturer’s Certificate of Analysis (CoA) as provided by CAP.
3-10
 To 
compare our results with other participants, the mean ±1SD and ±2SD for all peer institutions 
were plotted in parallel. For CD34, our results were compared only to participants using a dual-
stage platform for CD34 enumeration. As a control, we performed the same analysis for the 
%CD3 and absolute CD3 count (x10
6
) results, which were also included in the CAP-SCP 
challenges.  Internal results were compared to CoA and participant mean by paired t-test. In 
addition, the absolute and % difference in TNC, CD34 and CD3 results were calculated and 
compared. 
 
RESULTS 
External Allogeneic HPC-A Units.  
A total of 141 units HPC-A units for 131 patients were received from 40 external collection 
centers between 2011 and 2013 (Table 1). The vast majority of units (130, 92%) were collected 
at NMDP-affiliated centers. Sixty-nine units were from international collection centers and 72 
units were from domestic centers located in the United States. Domestic units were collected 
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from 23 NMDP-centers located in 15 states. Half of all domestic units (39/72, 54%) were 
collected at centers located in the same time zone (Eastern) as our facility.  
Most international units were from European donor centers. Germany was the largest 
international supplier of HPC-A units (55, 83%), with nearly 75% of all international units 
(49/66) coming from a single collection center.  A limited number of units (1-2 units) were 
received from 8 other countries including Poland (2), Denmark (1), England (3), Portugal (2), 
Sweden (2), Netherlands (1), Israel (2) and Australia (1). All non-NMDP units were from 
European collection centers. 
HPC-A units from domestic and international centers were comparable with few 
differences relative to donor characteristics, volume, total cell counts and cell dose (Table 2).  
   
Comparison of TNC Counts 
External and internal TNC counts were available in 128 units (Fig. 1). Paired counts were 
initially compared by linear regression (Fig. 2A), which showed a strong correlation (R=0.93) 
with a slope (m) of nearly 1 (m=0.86). The same tight correlation was observed for both 
international (R=0.92) and domestic units (R=0.93). The y-intercept (17.3) indicated a trend 
toward higher internal TNC counts, especially for domestic units.  
 The absolute and percent difference in TNC counts were also determined and compared 
(Fig. 2B, 2C). Overall, the TNC counts in 84% (108/128) units were within ±10% of each other 
(Fig 2C). For domestic units, there was a slight bias toward higher internal counts (64% units), 
although the median % difference was modest (-3.3%, Table 3). There was a trend (p=0.07) 
toward higher internal TNC counts for HPC-A units collected by centers located in the Eastern 
time zone.  
Page 8 of 33
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901 1 (434) 964-4100
Transfusion
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
9 
 
 External counts for international units were, in general, remarkably close to internal 
counts (Table 3). The mean and median % difference was 1.35% and 5.1%, respectively. We 
also examined TNC counts by continent and donor center since 75% of all international units 
came from a single donor center (107). As shown in Table 3, external TNC counts from donor 
center 107 tended to be 5% higher than internal counts (p=0.002).   
 
Comparison of CD34 Counts 
Paired external and internal CD34 counts were available in 122 (86.5%) units (Fig. 1). Like TNC 
counts, there was a close correlation between external and internal CD34 counts (Fig. 3A). As 
shown in Table 3, there was no significant difference in mean CD34 counts between external 
donor facilities and internal testing (p=0.73), with a median % difference of -1% (95% LA: -50, 
+47%; Fig 3C). Units that exceeded 95% LA tended to have lower CD34 counts. Overall, the 
internal CD34 count was within ±10% of the collecting facility’s yield in 72 units (59%), and 
within 20% in 94 units (77%).  
When examined by donor center location, 41/55 (74.5%) domestic units were within 
±10%, with a slight bias toward higher internal CD34 counts at our facility (median % 
difference= -0.8%; 95% LA: - 44.7, 43.1). The median % difference in CD34 counts for 
international units was -0.7% (Table 3; 95% LA: -45.5, 44.1), with nearly half falling within 
±10%.  
 
TNC and CD34 Results By Year 
We also compared TNC and CD34 counts by calendar year (Fig. 4). There was a small 
improvement in TNC correlation (Fig. 4A) between years 2011 (R= 0.84, m=0.6x) versus 2012 
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and 2013 (R= 0.96-0.98, m=0.93x-1x). There was no significant difference in TNC count by 
paired t-test (p=0.23-0.81, Table 3). There was also no significant difference in the relative 
distribution of international (43%-52%) versus domestic HPC-A units over the 3-year period. 
There was a good correlation between CD34 counts over time (Fig. 4B, R = 0.88-0.90). 
A comparison of counts by paired t-test showed no significant differences although there was a 
trend toward higher external counts in 2013 (p=0.07; Table 1, 4.6%). The higher external counts 
may reflect a10% increase in the number of domestic HPC-A units collected by centers located 
within the Eastern time zone (36% in 2013).  
 
Outlier Analysis 
A detailed analysis was performed in 10 cases in which the % difference in either TNC or CD34 
count was > 50% (Supplemental data, bold). Outlier counts were observed with both 
international (n=5) and domestic (n =5) units. A majority of units (6/10) were collected during 
the 2011 calendar year (6/33, 18%) versus 3 (6%) in 2012 and only 1 (2%) in 2013. All 6 cases 
in 2011 demonstrated either higher internal TNC (70-382%) or higher CD34 counts (63-94%). 
Four samples showed decreases in both TNC and CD34 counts, as well as lower cell viability 
(88-94%) suggesting some product deterioration during transit.    
 
Commercial PT Performance 
We participate in a commercial stem cell proficiency challenge offered biannually by CAP. We 
compared our results for TNC, CD34 and CD3 from 16 PT samples against the expected results 
based on the manufacturer’s CoA and the mean result (±1SD and ±2SD) for peer participants.  
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In general, our results for TNC counts fell within ±2SD for all challenges (Fig 5A). In 
paired t-tests, our results were -1.8% lower than the CoA (P=0.027: range, -23.4%, +15.3%) but 
4.9% higher than the participant mean (P=0.07; range, -9%, 6.8%). The average coefficient of 
variation (CV) across all TNC challenges was 9.2% ± 2.3%.  
 There was no CoA for %CD34, limiting our analysis to peer participants. As shown in 
Fig. 5B, internal results for %CD34 were within ±1SD for dual-stage users (P=0.48: CV range, 
9.3% - 46.9%). In contrast, the absolute CD34 count (x10
6
) was consistently low (-2SD, Fig. 5C) 
relative to the CoA (P=0.007) and participant mean (P=0.002: CV range, 14% -59.4%). Based on 
the recommendations of the UK NEQA program for HPC analysis, we reanalyzed the LMD file 
from each challenge keeping the 7-AAD gate open.
17
 There was no significant change in CD34 
results (data not shown). We also examined whether there was sufficient sample to collect the 
minimum number of cell events as recommended by ISHAGE (>75,000 CD45+ cells, >100 
CD45+,CD34+ cells).
19
 Although sufficient CD45+ events were collected, the minimum number 
of CD34+ events could not reached in 3 samples (range, 41 – 67 CD34 cells).  
   Because of our consistently low absolute CD34 counts, we also examined our 
performance with %CD3 and absolute CD3 (x10
6
) counts during the same challenges. Unlike 
CD34+ cells, CD3+ cells are plentiful and account for 55-84% of all peripheral blood 
lymphocytes.
25
 As shown in Fig 5D and 5E, the %CD3 (P=0.0005) and absolute CD3 counts (P= 
0.0001) were significantly lower than the participant mean. The lower TNC, %CD3 and absolute 
CD3 counts suggest some sample deterioration prior to receipt and testing.  
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DISCUSSION 
The TNC and viable CD34 counts are critical to clinical decision-making during stem cell 
collection and transplantation. Numerous clinical studies over two decades have confirmed the 
importance of sufficient CD34 cells to ensure adequate long-term engraftment.
22,26-28 
  In bone 
marrow transplantation, TNC count is often used as an intra-operative surrogate assessment of 
harvest efficacy, while both TNC and CD34 cell dose are correlated with transplant 
outcomes.
26,27
 Likewise, both TNC and CD34 counts are important for determining the quality of 
umbilical cord blood for cryopreservation and transplantation.
28
 In donors undergoing peripheral 
blood stem cell collection, the number of circulating CD34 cells determine the timing of 
collection and the number of procedures required.
29
 As a result, TNC, CD34 and cell viability are 
considered critical analytes subject to PT.
1,2
  
In general, PT for TNC and WBC counts is relatively easy given the reproducibility and 
precision of current automated cell analyzers.
30,31
  In contrast, CD34 PT has proved particularly 
challenging due to the complexity of testing, and host of pre-analytical and technical factors that 
can separately, and synergistically, influence test results.
12-19,32
 Moreover, CD34 enumeration is 
a rare event analysis, which presents additional difficulties for quality control, precision and 
accuracy.
33
 Over the last 20 years, cell therapy PT challenges have been instrumental in 
identifying many technical and reagent factors that can impact CD34 testing and serve as the 
basis for today’s current best practices. These include the use of class II and class III anti-CD34 
mAb, preferably as CD34-PE conjugate; a multiparameter sequential gating strategy; the 
importance of acquiring sufficient data events, and inclusion of viability staining.
13,14,16,17,19
 
Single platform testing, which requires the addition of fluorescent beads to samples, is also 
reported to increase accuracy since it allows a direct internal measure of the number of CD34 
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cells per volume tested.
12,13,17,33
 Dual platform testing is felt to be less accurate although studies 
have reported equivalent results when ISHAGE gating is used.
14,34
  
Pre-analytical variables also influence CD34 PT performance and may account for 40% 
of the variation observed between participants.
20 
One important pre-analytical factor is the type 
of sample: PT samples prepared from HPC-A, which are enriched for CD34 cells, tend to have 
closer agreement than peripheral blood samples.
20,34
 Bone marrow is also prone to high 
variability due to heterogeneity in CD34 staining and cell granularity.
34
 Samples for CD34 PT 
have included stabilized, commercial CD34+ tissue culture line (KG1);
35
 stabilized CD34+ acute 
myeloid leukemia cells;
13
 heparinized whole blood;
20
  blood diluted with donor plasma;
32
 
peripheral blood containing a cell preservative;
12-16
 fresh HPC-A or marrow diluted in 
phosphate-buffered saline
20
 or tissue-culture media (RPMI, X-VIVO
TM
);
3-10,18
 and thawed, 
cryopreserved HPC-A resuspended in tissue culture media (RPMI, Dulbecco’s).
16,18
 
Other pre-analytical factors are the homogeneity of the samples during central processing 
and aliquoting, sample stability and reproducibility during storage and transport, and sample 
processing upon receipt.
36
 Long delays or improper storage during transport can impact cell 
content between participating centers,
18
 particularly if cells were in the early stages of apoptosis. 
Studies have shown that 7-AAD, which only measures membrane integrity, is unable to detect 
cells in early apoptosis and/or poor proliferative capacity.
16,37,38
  To improve sample stability, 
some manufacturers add or collect blood in a stabilizing agent.
12-17
 In the United States, CAP-
SCP PT samples are prepared from either peripheral blood or HPC-A, re-suspended in 
heparinized X-VIVO 10, a serum-free hematopoietic cell media marketed for CD34 and 
lymphocyte cell cultures that is supplemented with 10% autologous serum.
39
  Finally, laboratory 
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differences in sample processing (cell lysis reagent, wash/no wash) can introduce additional 
sample variation prior to analysis.
14,20,40
  
Our data suggest that allogeneic HPC-A products can also serve as a PT challenge, with 
many advantages over commercial PT samples. HPC-A samples are large volume and 
significantly less subject to aliquot and sampling error. In addition, HPC-A are not subject to 
additives that may alter cell characteristics. Moreover, HPC-A products are packaged and 
transported using an established validated method to ensure cell viability and stability.   
Allogeneic HPC-A are still subject to inter-laboratory variability due to sample 
processing and technical factors including testing platform, instrumentation and software, 
staining reagents, pipetting, gating strategy, number of acquired events, and operator 
experience.
12-18,20
  Nonetheless, we observed a satisfactory performance between our results and 
the majority of external sites. Overall, the median % difference for TNC (-0.15%) and CD34 (-
1.1%) counts was very low, with 85% TNC and 59% CD34 counts falling within ±10% of the 
external facility. These results compare favorably to UK NEQA PT program, in which 
participants are expected to fall within the median 50% (25
th
-75
th
 percentile) ± 15% over 3 
successive challenges.
14,17
  
Our experience using allogeneic HPC-A products as a paired PT challenge was 
significantly better than CAP-SCP PT challenges. TNC counts using the Sysmex XE-5000 were 
slightly lower than the CoA but still within ± 2SD. Likewise, the results for %CD34 fell within 
±1SD for institutions using dual platform testing. In contrast, we consistently had absolute CD34 
values that fell near or below 2SD, even after re-analysis without 7-AAD gating per UK NEQA 
guidelines.
17
  A comparison of %CD3 and absolute CD3 counts during the same challenges also 
showed significantly lower %CD3 and absolute CD3 counts. Altogether, we believe that the 
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lower mean TNC counts, %CD3 and absolute CD3 suggest some sample degradation. Stability 
studies with the Sysmex XE-5000 have shown a 4% decrease in lymphocyte count within 24 
hours at cool temperatures.
41
 Probable sample degradation was also evident during flow 
cytometric analysis in many samples. Sample degradation would also contribute to our inability 
to reach the minimum number of CD34 events in 18% of samples.
19
  
In addition to pre-analytical factors, there were three technical differences that could also 
contribute to the variability we observed with commercial PT samples. One is our use of a newer 
multichannel (10-color) flow cytometer, which was an outlier among CAP participants. Both 
flow cytometry instrumentation and analytical software are variables effecting CD34 PT testing 
and lymphocyte subtyping.
14,42
 Furthermore, we use a modified ISHAGE protocol that includes 
CD14-FITC and a different CD45 fluorochrome (ECD). The inclusion of CD14 for gating is 
recommended in the SIHON protocol developed in the Netherlands.
14,20-22
 Gating for 
CD34+CD14- cells excludes nonspecific CD34 binding by Fcγ receptors on monocytic cells, 
which are upregulated by G-CSF and GM-CSF, as well as CD34+CD14+ early monocytes 
present in marrow and peripheral blood (5-10%).
20-22,34
 It is reported that the addition of CD14 in 
cord cell analysis can decrease the %CD34 cells by 0.9 to 47%.
21
 Similarly, Brecher et al 
reported that institutions using CD14 had a lower %CD34 in 40% to 80% of PT samples.
18
 In 
contrast, Levering et al found no significant difference in CD34 results between ISHAGE and 
SIHON gating strategies after reviewing the results of 64 PT samples.
14
 Likewise, our %CD34 
was very close to the mean for dual platform users in CAP-SCP challenges (Fig. 5B). Finally, we 
observed a very good concordance in CD34 enumeration between our center and other facilities, 
with a slight positive bias toward higher internal CD34 counts (median, 1%) using our modified 
ISHAGE protocol. 
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Some of the earliest CD34 PT challenges were plagued by wide inter-laboratory 
variability, especially with fresh samples.
18,20,32,35
  Chang and Ma, reporting on an Australasian 
PT challenge using samples diluted in human plasma, showed that 65% of centers were outside 
the recommended range (±10% median).
32
 In an early PT challenge involving 21 samples and 10 
participating centers in North America, the CV for %CD34 ranged from 3.7% to 159%.
18
 Even 
when participants were provided both reagents and a standard gating protocol, CVs for %CD34 
ranged from 34% to 106% due to nontechnical factors.
20
 A survey of current CAP-SCP 
challenges shows similar variability: The CV for absolute CD34 count ranges from 14-59.4% for 
dual platform and 11% - 54.5% for single platform.
3-10
  
Better results are reported using stabilized and/or preserved samples, often coupled with 
central review of LMD files and gating strategies for poor performing laboratories.
13,14,16,17
  The 
former New York State Department of Health CD34 PT program, which used short-term 
stabilized cell samples, was able to progressively improve PT challenge performance.
16
  
Likewise, the UK NEQA program prepares and distributes preserved samples that stably retain 
CD34 cell expression for up to a year.
12,13,17
 As a result, the UK NEQA program has decreased 
variability to CV<10%.
13,17
 The Netherlands has also converted to the use of long-term stabilized 
samples for their CD34 PT program with a significant decrease in variability.
14
 The use of 
stabilized PT samples, however, does have some caveats.
17
 The stabilizer impacts cell 
permeability, affecting both SS and 7-AAD staining. As a consequence, participants are advised 
to exclude 7-AAD from gating and extend the SS-gate.
17
 Conversely, the ability of preservation 
to manufacture 7-AAD+, CD34+, CD45+ cells can be exploited for quality control. Gutensohn et 
al validated the use of commercial, preserved CD34+ cells as an internal positive control for 
routine CD34 analysis.
43
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In summary, we have demonstrated that allogeneic HPC-A products can serve as an 
external PT challenge for TNC and CD34 enumeration. HPC-A products may be a more accurate 
assessment of laboratory proficiency than some commercial PT samples, which are subject to 
preanalytic variation due to sample preparation techniques, sample homogeneity and sample 
stability.
33
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ABBREVIATIONS: 
7-AAD, 7-aminoactinomycin D; CAP-SCP, College of American Pathology – Stem Cell 
Processing; CoA, Certificate of Analysis; FITC, fluorescein isothiocyanate; ISHAGE, 
International Society for Hematotherapy and Graft Engineering; 95% LA, 95% limits of 
agreeability; LMD, list mode data; NMDP, National Marrow Donor Program; PE, phycoerythrin; 
PT, proficiency test/testing; TNC, total nucleated cell count; SS, side scatter; UK NEQA, United 
Kingdom National External Quality Assurance program. 
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Table 1. External donor center demographics 
 
Collection Centers No. Centers No. Units 
All Donor Centers 40 141 
   
Internationa  17 69 
NMDP 7 58 
Non-NMDP 10 11 
No. Countries 9  
Europe 14 66 
Mideast 2 2 
Australia 1 1 
   
Domestic  23 72 
NMDP 23 72 
Non-NMDP 0 0 
No. States 15  
Eastern*  8 39 
Central*  4 14 
Mountain*  2 12 
Pacific* 1 7 
 
* Time zone of external donor center.  
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Table 2. Comparison of allogeneic HPC-A Units by donor center location* 
 
Variable International Domestic P 
No. Donors 65 66 - 
Gender (M/F) 55/10 49/17 0.15 
Age, years 33.1 ± 9.3 34.5 ± 10.3 0.40 
    
Total Units 69 72 - 
No. Split Units 4 6 - 
Unit Volume, mL 360 ± 108 348 ± 109 0.53 
TNC, x 10
9*
 79.35 ± 27.56 83.78 ± 38.92 0.44 
Cell Viability (%)* 93.7 ± 11.8 96.4 ± 12.0 0.17 
% MNC* 68.0 ± 20.0 67.6 ± 20.2 0.90 
Total MNC, x 10
9*
 50.15 ± 14.18 52.37 ± 19.49 0.44 
MNC/kg, x 10
8*
 6.35 ± 3.00 7.18 ± 5.37 0.26 
% CD34* 0.83 ± 0.36 0.87 ± 0.51 0.88 
Total CD34, x 10
6*
 638.65 ± 272.42 696.71 ± 357.75 0.31 
CD34/kg, x 10
6*
 8.41 ± 5.58 9.01 ± 8.30 0.61 
Hematocrit (%)* 3.9 ± 1.8 4.5 ± 2.4 0.14 
Platelet, x 10
3
/µL* 2154 ± 959 2525 ± 1018 0.03 
 
*  Based on internal cell counts. 
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Table 3. Paired comparison of internal and external TNC and CD34 Counts* 
  Total Cell Counts  External – Internal 
 No. 
Units 
External
†
 Internal
‡
 P
§
 [difference]
||
 
(median) 
% difference
¶
 
(median) 
TNC (x10
9
)       
All Units 128 82.06 ± 33.98 82.22 ± 31.82 0.88 -0.2 (-0.2) -3.7 (-0.15) 
2011 32 78.90 ± 35.46 79.61 ± 27.24 0.57 -20.0 (0.2) -14.9 (0.1) 
2012 50 85.78 ± 31.88 87.47 ± 38.08 0.81 -0.3 (-1.0) -0.6 (-1.4) 
2013 46 80.31 ± 34.43 76.88 ± 32.80 0.23 1.3 (1.5)  0.97 (2.0) 
       
International Units 67 78.67 ± 24.64 76.49 ± 25.08 0.87 2.1 (3.3) 1.35 (5.1) 
Europe 64 78.00 ± 22.15 76.22 ± 24.08 0.14 1.8 (3.4) 1.89 (5.2) 
NMDP #107 49 79.50 ± 17.98 76.05 ± 18.24 0.002 2.7 (3.4) 4.29 (5.4) 
Other  15 76.77 ± 32.57 76.77 ± 58.03 0.28 -1.6 (0.9) -8.96 (-2.1) 
Mideast 2 104.5 ± 87.5 89.19 ± 65.8 0.50 15.3 (15.3) 9.2 (9.2) 
Australia 1 65.88 68.62 - -2.74 -4.1 
       
Domestic Units 61 84.52 ± 40.64 87.08 ± 35.85 0.17 -2.6 (-2.4) -9.3 (-3.3) 
Eastern  35 78.08 ± 35.17 83.96 ± 30.51 0.07 -4.9 (-2.8) -15.1 (-3.6) 
Central  10 89.65 ± 45.24 81.45 ± 33.86 0.24 6.2 (0.9) 2.5 (-2.3) 
Mountain  12 81.45 ± 32.77 84.11 ± 32.71 0.12 -2.6 (-1.0) -3.6 (-1.7) 
Pacific  4 142.23 ± 62.67 146.16 ± 52.77 0.71 -3.9 (-3.4) -4.9 (-2.3) 
       
Total CD34 (x10
6
)       
All Units 122 665.67 ± 315 669.25 ± 341 0.80 -4.9 (-5.5) -3.1 (-1.1) 
2011 30 687.39 ± 311 704.17 ± 381 0.61 -16.8 (-20.7) -11.4 (-9.8) 
2012 48 691.37 ± 311 724.58 ± 366 0.15 -21.2 (-9.8) -6.8 (-2.5) 
2013 44 613.12 ± 253 578.71 ± 261 0.07 34.4 (19.8) 4.6 (3.2) 
       
International Units 67 640.18 ± 274 655.0 ± 286 0.29 -12.2 (4.1) -5.0 (-0.7) 
Europe 64 630.45 ± 269 649.46 ± 285 0.21 -15.8 (0.6) -5.3 (-0.8) 
NMDP #107 48 676.14 ± 278 696.4 ± 98 0.21 -16.1 (5.3) -4.6 (-0.4) 
Other 16 493.14 ± 186 508.5 ± 186 0.68 -15.3 (-9.5) -7.3 (-1.3) 
Mideast 2 714.5 ± 401 650.9 ± 365 0.24 63.6 (63.6) 0 (0)** 
Australia 1 1114 1043 - -71 -6.4% 
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Domestic Units 55 696.71 ± 358 686.15 ± 400 0.68 -16.08 (-3.1) -0.8 (-0.8) 
Eastern  34 684.69 ± 355 688.38 ± 398 0.91 -5.22 (4.7) -1.8 (-2.0) 
Central  9 564.78 ± 267.2 564.78 ± 221.5 0.61 26.4 (33) -3.0 (-5.1) 
Mountain 10 809.44 ± 459 799.47 ± 548 0.88 9.97 (-49.6) -0.3 (-10.7) 
Pacific  2 812.2 ± 108 627.7 ± 216 0.25 184.5 (184.5) 23.8 (23.8) 
 
* Limited to HPC-A products with both external and internal testing results (see Figure 1) 
† Absolute counts from external donor facility, reported as x ± SD 
‡ Internal absolute counts, reported as x ± SD 
§ Paired t-test 
|| Mean (median) difference in absolute counts between external donor center and internal results, 
where external – internal count. 
¶ Mean (median) percent (%) difference in absolute counts between external donor center and 
internal results, where ([external – internal count] ÷ 2). 
** Percent difference was -8.9% and +8.9% (n=2) 
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FIGURE LEGENDS 
 
Figure 1.  Paired data sets by donor center location, CD34 count and TNC count. 
 
Figure 2. Comparison of TNC counts in allogeneic HPC-A products by donor center location. 
A) Correlation between internal and external TNC count (x10
8
).  B) Absolute difference in TNC 
count (external –internal). C) Percent (%) difference in TNC count. Vertical lines indicate ±1SD 
(- - ) and ±2SD (= =). 
 
Figure 3. Comparison of CD34 counts in allogeneic HPC-A products by donor center location. 
A) Correlation between internal and external CD34 count (x10
6
). B) Absolute difference in 
CD34 count (external – internal). Vertical lines indicate ±1SD (- - ) and ±2SD (= =). C) 95% LA 
for CD34 counts.  Percent (%) difference CD34 (± 1.96 SD, hatched line) plotted against the 
mean CD34 count from both facilities. 
 
Figure 4. Comparison of TNC (A) and CD34 (B) counts by calendar year.  
 
Figure 5. Internal performance with commercial cell therapy PT challenges. A) Internal TNC 
count against TNC count listed on CoA.  B) Internal %CD34 against mean %CD34 for dual 
platform. C) Internal absolute CD34 count against CD34 count listed on CoA.  D) Internal 
%CD3 against mean %CD3 for dual platform.  E) Internal absolute CD3 count against the mean 
CD3 count. Gray lines show the mean (, solid line), ±1SD (⋅⋅⋅⋅⋅, dotted line) and ±2SD ( - 
, hatched line) for dual platform users. 
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 141 Allogeneic HPC-A Units 
 69 International Collection Centers 
 72 Domestic (USA) Collection Centers 
 
 
  
 128 Paired TNC Counts 13 Missing Data Pairs 
 67 International Units 2 International  
 61 Domestic Units 11 Domestic  
 
  
 
 122 Paired CD34 Counts 19 Missing Data Pairs 
 67 International Units 2 International 
 55 Domestic Units 17 Domestic 
  
 
 
 120 Paired CD34 and TNC Counts 21 Missing Data Sets 
 66 International Units 3 International  
 54 Domestic Units 18 Domestic 
 
 
 
 
 
 
 
Figure 1
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Supplemental Data, Table 1. HPC-A units with discrepant counts (% difference 50% or greater)*  
 
Cell 
Viability 
TNC Count (x 10
9
)  CD34 Count (x 10
6
)  Donor 
Center 
 
Year External Internal % Difference*  External Internal % Difference*  
           
99% 9.84 88.02 -79 %  1566 1021 +35 %  Europe 2011 
94% 22.99 61.33 -136 %  564 668.2 -18.5%  USA 2011 
98% 7.60 32.56 -382 %  172 159.5 + 7%  USA 2011 
           
94% 64.51 73.39 -15 %  382.6 595.5 -56 %  Europe 2012 
98% 162.72 169.54 -4 %  260.3 423.9 -63 %  Europe 2011 
94% 66.13 66.50 +0.9 %  266 452 -70 %  Europe 2011 
88% 169.73 198.50 -17%  305.5 595.5 -94%  Europe 2011 
99% 40.18 39.65 +1.3%  447.8 223.9 +50 %  USA 2012 
97% 95.1 89.36 -7%  778.6 294.9 +62%  USA 2013 
99% 86.51 92.91 -7 %  709.4 241.6 +66 %  USA 2012 
           
 
* % Difference= (External Count – Internal Count)/External Count x 100 
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